NCT00975650View on ClinicalTrials.gov

Efficacy and Tolerability of an Intra-Nasal Testosterone Product

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hypogonadism
Interventions
DRUG

Nasobol®

Intra-nasal Testosterone (2 syringes), b.i.d.

DRUG

Androderm® (Positive Control)

QD administration

Trial Locations (6)

33169

Cetero Research, Miami Gardens

67221

Clinical Research Institute, Wichita

71106

Regional Urology, LLC, Shreveport

78229

dgd Research Inc., San Antonio

85712

Quality of Life Medical & Research centre, Tucson

91505

Providence Clinical Research, Burbank

Sponsors
All Listed Sponsors
lead

Acerus Pharmaceuticals Corporation

INDUSTRY

NCT00975650 - Efficacy and Tolerability of an Intra-Nasal Testosterone Product | Biotech Hunter | Biotech Hunter